206 related articles for article (PubMed ID: 31036835)
1. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.
Koster J; Plasterk RHA
Sci Rep; 2019 Apr; 9(1):6577. PubMed ID: 31036835
[TBL] [Abstract][Full Text] [Related]
2. The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Martin MV; Aguilar-Rosas S; Franke K; Pieterse M; Langelaar JV; Schreurs R; Bijlsma MF; Besselink MG; Koster J; Timens W; Khasraw M; Ashley DM; Keir ST; Ottensmeier CH; King EV; Verheij J; Waasdorp C; Valk PJM; Engels SAG; Oostenbach E; van Dinter JT; Hofman DA; Mok JY; van Esch WJE; Wilmink H; Monkhorst K; Verheul HMW; Poel D; Hiltermann TJN; Kempen LCLTV; Groen HJM; Aerts JGJV; Heesch SV; Löwenberg B; Plasterk R; Kloosterman WP
Cancer Immunol Res; 2024 Jun; 12(6):759-778. PubMed ID: 38573707
[TBL] [Abstract][Full Text] [Related]
3. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
5. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
6. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
8. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
9. RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines.
Shen L; Zhang J; Lee H; Batista MT; Johnston SA
Sci Rep; 2019 Oct; 9(1):14184. PubMed ID: 31578439
[TBL] [Abstract][Full Text] [Related]
10. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
11. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Wang RF; Johnston SL; Zeng G; Topalian SL; Schwartzentruber DJ; Rosenberg SA
J Immunol; 1998 Oct; 161(7):3598-606. PubMed ID: 9759882
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines.
Chen T; Hu R; Wan Y; Sun F; Wang Z; Yue J; Chen J; Han G; Wei G; Dong Z
Biochem Biophys Res Commun; 2020 May; 525(3):607-613. PubMed ID: 32115148
[TBL] [Abstract][Full Text] [Related]
14. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
15. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
16. FusionNeoAntigen: a resource of fusion gene-specific neoantigens.
Kumar H; Luo R; Wen J; Yang C; Zhou X; Kim P
Nucleic Acids Res; 2024 Jan; 52(D1):D1276-D1288. PubMed ID: 37870454
[TBL] [Abstract][Full Text] [Related]
17. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
18. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
19. Mutation position is an important determinant for predicting cancer neoantigens.
Capietto AH; Jhunjhunwala S; Pollock SB; Lupardus P; Wong J; Hänsch L; Cevallos J; Chestnut Y; Fernandez A; Lounsbury N; Nozawa T; Singh M; Fan Z; de la Cruz CC; Phung QT; Taraborrelli L; Haley B; Lill JR; Mellman I; Bourgon R; Delamarre L
J Exp Med; 2020 Apr; 217(4):. PubMed ID: 31940002
[TBL] [Abstract][Full Text] [Related]
20. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
